Morgan Stanley Acelrx Pharmaceuticals Inc Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.2 - $0.35 $7,309 - $12,792	36,549 Added 63.79%	93,841 $20,000
Q2 2022 Oct 27, 2022	SELL	$0.18 - $0.29 $233 - $375	-1,296 Reduced 2.21%	57,292 $14,000
Q2 2022 Aug 15, 2022	SELL	$0.18 - $0.29 $233 - $375	-1,296 Reduced 2.21%	57,292 $14,000
Q1 2022 Oct 27, 2022	BUY	$0.28 - $0.61 $362 - $790	1,296 Added 2.26%	58,588 $17,000
Q1 2022 May 13, 2022	BUY	$0.28 - $0.61 $2,585 - $5,632	9,234 Added 18.71%	58,588 $17,000
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $44,575 - $92,789	-90,970 Reduced 64.83%	49,354 $27,000
Q3 2021 Nov 15, 2021	BUY	$0.93 - $1.51 $130,501 - $211,889	140,324 New	140,324 $142,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.